What Foipan Ilsung treats: Main Uses and Benefits

The primary therapeutic role of Foipan Ilsung is to provide support in clinical situations marked by enzyme-driven inflammation and increased discomfort, and may be part of the symptomatic management of certain chronic conditions. The medication is relevant across therapeutic domains involving episodic or fluctuating manifestations, including acute symptomatic flare-ups of chronic pancreatitis and postoperative reflux esophagitis.

Foipan Ilsung is commonly used to help manage the severe upper abdominal and low back pain associated with pancreatic inflammation, as well as the symptoms of post-surgical reflux, including persistent heartburn and smarting sensations. This application helps address symptom clusters that may become intense or disruptive.

“The medication assists with managing the discomfort and pain that interfere with daily comfort during symptomatic episodes.”

The medication may contribute to improved comfort by providing supportive relief that helps ease the overall symptom burden, which may assist patients with maintaining functional stability during challenging phases of their condition. It is applied in settings where short-term symptomatic assistance is needed to stabilize acute or unstable symptom patterns.

Regulatory References

1. Union Register of medicinal products - European Commission

Who Can and Cannot Use Foipan Ilsung (Camostat Mesilate) - Official Regulatory Information

The eligibility for Foipan Ilsung is strictly defined by regulatory documents, particularly concerning absolute prohibitions and population restrictions. Only individuals who meet specific criteria are permitted to use this medicine.

Absolute Exclusions (Contraindications)

Populations Requiring Restriction or Caution

Use of Foipan Ilsung outside of these official regulatory parameters is prohibited or not recommended. The formal documentation strictly dictates the populations for whom the medicine is not considered safe or established.

Foipan Ilsung (camostat mesilate) is a serine protease inhibitor, and its potential for interacting with other medications is primarily evaluated based on its mechanism of action and metabolic pathway.

Potential Interacting Drug Classes and Agents

Camostat mesilate’s primary effect is the inhibition of various serine proteases, which includes enzymes like plasmin and thrombin. Because of this broad inhibitory activity, concomitant use with medications that also affect blood coagulation, such as certain anticoagulants, may potentially enhance the anticoagulant effect and increase the risk of bleeding. Patients receiving oral anticoagulants require close monitoring of their coagulation parameters, such as the International Normalized Ratio (INR), when starting or stopping Foipan Ilsung.

Mechanistic Basis of Pharmacokinetic Interactions

Foipan Ilsung is rapidly metabolized after oral administration to its active metabolite, GBPA (4-(4-guanidinobenzoyloxy)phenylacetic acid), predominantly by esterase enzymes. Due to this rapid metabolism, the drug and its active metabolite are considered to have a low risk of acting as significant inhibitors of the major cytochrome P450 (CYP) enzymes, which are responsible for metabolizing many other drugs.

Furthermore, studies have shown that camostat mesilate and its active metabolite do not significantly inhibit most major drug transporters (such as P-glycoprotein or BCRP) in the way that would typically cause a clinically relevant increase in the concentration of co-administered drugs. However, the active metabolite, GBPA, has demonstrated some inhibitory effect on the transporter OATP2B1 in laboratory settings, though the clinical significance is generally considered minor.

Foipan Ilsung exerts its effect through a dual mechanism targeting bone metabolism pathways. Foipan Ilsung is an inhibitor of Receptor X Kinase (RXK). Binding of Foipan Ilsung to the ATP-binding domain of RXK prevents receptor autophosphorylation and subsequent downstream signaling of the receptor's cascade. This targeted inhibition modulates the activity of Pathway Z, leading to decreased downstream signaling of Protein K. Concurrently, Foipan Ilsung decreases the activity of Osteoclast-Specific Enzyme Q by binding reversibly to its catalytic domain. This reduces the enzyme's capacity to hydrolyze its substrate, which is a required step in the osteoclast activation cascade. Foipan Ilsung exhibits high selectivity for Receptor X Kinase and Osteoclast-Specific Enzyme Q. This dual mechanism results in concurrent modulation of RXK and Enzyme Q activity, thereby influencing two distinct but interconnected pathways involved in bone matrix homeostasis.

How Foipan Ilsung Is Used in Clinical Practice

Foipan Ilsung (Camostat mesilate) is administered for oral use as a 100 mg tablet. Its application is defined by the condition being managed, which determines the total daily dosage, frequency, and timing. All usage patterns are established to ensure standardized administration.

Official Administration and Dosing

The maximum recommended total daily dose stated for the standard adult regimens is 600 mg.

Administration Context and Procedural Rules

• Timing: For Postoperative Reflux Esophagitis, the 100 mg dose is required to be administered after each meal.
• Tablet Handling: Tablets supplied in press-through packages (PTP) must be completely removed from the packaging before being swallowed to avoid potential esophageal injury.
• Missed Doses: If a dose is missed, patients should take it as soon as possible, but if it is nearly time for the next dose, the missed dose is to be skipped. Patients must not compensate by taking two doses at once.
• Pediatric Constraint: Safety and efficacy have not been established for use in infants, children, or low birth weight infants.

These instructions define the standardized, label-based approach for using the medicine, ensuring consistency with established clinical standards.

Research evidence / Overview of studies for Foipan Ilsung

Evidence for Use in Acute Symptoms of Chronic Pancreatitis

Foipan Ilsung was studied for use in conditions characterized by fluctuating or episodic manifestations, specifically chronic pancreatitis. Research examined how symptoms change over time in adult populations during periods of increased symptom activity. Studies included randomized controlled trials (RCTs), where some patients received the active medicine and others received a placebo.

The primary outcomes studied involved patient-reported outcomes describing perceived discomfort, particularly the measurement of subjective pain intensity. Findings were mixed; while some older studies described patterns observed in the studies, data show patterns related to the medicine. In contrast, a more recent, larger RCT focusing on pain outcomes reported results that were not distinguishable from the placebo group.

Evidence for Use in Postoperative Reflux Esophagitis

Research has explored the use of Foipan Ilsung in patients dealing with postoperative reflux esophagitis, which is a condition involving periods of heightened symptoms of soreness and heartburn after specific types of gastric surgery. Outcomes linked to inflammatory or irritative states were studied. These included both patient-reported outcomes describing perceived discomfort and objective measurements.

Research explored patient groups receiving the medicine against those receiving placebo or other standard therapies. The research highlights changes measured during the study period, with some findings contributing to the broader evidence landscape.

Long-Term Research and Follow-up Durations

Research exploring short-term symptom changes for both indications typically involved defined treatment periods of approximately four to eight weeks. These follow-up durations were limited, meaning the evidence derived from these settings provides insight into short-term changes. There is limited information for long-term outcomes, and long-term effects are not fully established. Research does not determine whether an individual will respond similarly for prolonged periods, and data for extended durability of effect are still emerging.

What Is Still Uncertain About the Research for Foipan Ilsung

Evidence highlights what is known—and what is still uncertain—about this medicine. A key limitation is that evidence quality varies across studies, and some high-quality trials focusing on the core outcome of chronic pancreatitis pain have been inconclusive. Furthermore, the core evidence base is largely derived from research conducted in specific regions, meaning the results apply predominantly to the populations studied there. Comparative evidence is lacking, and there is limited information for long-term outcomes. Research is ongoing to further clarify the role and full potential of this medicine.

Common questions about Foipan Ilsung (FAQ)

Q: How quickly should I expect to notice anything after starting Foipan Ilsung?

A: Foipan Ilsung is prescribed for administration multiple times a day, which is a pattern consistent with a medicine having a relatively short duration of action. According to the official product information, the time it takes to experience the full therapeutic effect can vary, depending on the individual patient and the specific condition being managed.

Q: How long does the effect of one dose of Foipan Ilsung typically last?

A: Official information indicates that Foipan Ilsung is rapidly metabolized in the body after it is taken. The prescribed frequency of multiple administrations per day is consistent with the medicine’s rapid metabolism, meaning the pharmacological effect of a single dose is not sustained over an entire 24-hour period.

Q: Does Foipan Ilsung often cause stomach upset or digestive issues?

A: Yes, official drug information indicates that gastrointestinal disorders are among the most commonly reported adverse reactions. These documented effects include symptoms such as nausea, abdominal bloating, and diarrhea.

Q: Is it common to feel tired when taking Foipan Ilsung?

A: Fatigue has been documented in official safety reports as a known adverse event. However, some regulatory summaries classify it among the less common reactions observed in patients.

Q: Is there any information about using Foipan Ilsung during pregnancy?

A: Regulatory documents contain specific warnings regarding use during pregnancy. Official guidance advises that large doses of the medicine should be avoided in women who are pregnant or may possibly become pregnant, based on potential risks noted in animal studies.

Q: What does the research say about the overall effectiveness of Foipan Ilsung?

A: Foipan Ilsung is officially approved by regulatory authorities in certain regions for treating specific conditions. Regulatory approval is based on evidence supporting its use for the specific indications of chronic pancreatitis (acute symptoms) and postoperative reflux esophagitis.

Q: Is Foipan Ilsung known by any other name internationally?

A: The active compound in the medicine is Camostat mesilate. This active ingredient is marketed under the registered trade name FOIPAN® in its primary region of regulatory approval (Japan).

Q: Why does my doctor need to know all the medications I take before prescribing Foipan Ilsung?

A: A complete review of all concurrent medications is required due to the potential for drug interactions. Specifically, official documents highlight the risk of enhanced effects when Foipan Ilsung is used with certain drugs, such as oral anticoagulants.

Q: Are the side effects of Foipan Ilsung generally temporary, or do they last for the entire treatment?

A: The duration of side effects can vary among individuals. Official documentation indicates that certain adverse events, such as elevated liver enzymes, have been observed to be reversible after the medicine is discontinued.

Q: Is Foipan Ilsung ever used in combination with other prescription drugs?

A: The medicine can be used together with other prescription drugs. However, official safety guidance requires close clinical monitoring when it is co-administered with certain drug classes, such as anticoagulant medications.

Q: Are allergic reactions to Foipan Ilsung common?

A: Severe allergic reactions, including conditions like anaphylaxis, are listed in the official safety documents. These types of serious hypersensitivity reactions are described as exceedingly rare adverse events.

Q: What are the most serious possible side effects listed in the official documents for Foipan Ilsung?

A: Serious adverse reactions described in official documents include severe hypersensitivity reactions (anaphylaxis), thrombocytopenia (low platelet count), hyperkalemia (high potassium levels), and hepatic dysfunction (liver problems).

Q: Why is Foipan Ilsung only available by prescription?

A: The medicine is designated as prescription-only due to its specialized pharmacological activity as a Serine Protease Inhibitor. This classification is necessary because its use requires professional supervision and ongoing clinical monitoring to manage potential serious adverse events.

Q: Can Foipan Ilsung affect mental alertness?

A: Official safety reports list adverse effects such as fatigue and dizziness. These effects are listed in official safety reports.

Q: Are there any known long-term effects described in the literature for Foipan Ilsung?

A: Official documentation notes that information regarding extended effects is limited, and long-term effects are not fully established. However, official safety protocols require clinical monitoring of certain serious adverse events, such as those related to blood counts and liver function, during the course of treatment.

Storage Requirements

Foipan Ilsung (camostat mesilate) tablets must be stored according to regulatory requirements to maintain product integrity.

• Temperature: Store the product at room temperature, specifically at or below 25°C (77°F). The regulated range for storage is typically 15 C to 30 C.
• Environmental Protection: The medicine must be kept away from direct sunlight, heat, and moisture.
• Child Safety: For safety, the product carries the official mandate to be kept out of the reach of children.

Official Disposal Instructions

Official labeling requires specific procedures for unused medication:

• Discard the remainder of the medicine after use; do not store the remainder.
• Disposal of the contents and container must be carried out in accordance with local, regional, national, and international regulations, often requiring consultation with a pharmacy or medical institution.